Target Price | $61.20 |
Price | $58.50 |
Potential |
4.62%
register free of charge
|
Number of Estimates | 21 |
21 Analysts have issued a price target Kymera Therapeutics Inc 2026 .
The average Kymera Therapeutics Inc target price is $61.20.
This is
4.62%
register free of charge
$92.40
57.95%
register free of charge
$53.53
8.50%
register free of charge
|
|
A rating was issued by 26 analysts: 25 Analysts recommend Kymera Therapeutics Inc to buy, 1 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Kymera Therapeutics Inc stock has an average upside potential 2026 of
4.62%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 47.07 | 77.08 |
40.11% | 63.76% | |
EBITDA Margin | -529.72% | -369.04% |
157.03% | 30.33% | |
Net Margin | -475.59% | -319.60% |
154.33% | 32.80% |
22 Analysts have issued a sales forecast Kymera Therapeutics Inc 2025 . The average Kymera Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
8 Analysts have issued an Kymera Therapeutics Inc EBITDA forecast 2025. The average Kymera Therapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
23 Kymera Therapeutics Inc Analysts have issued a net profit forecast 2025. The average Kymera Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -2.98 | -3.49 |
18.25% | 17.11% | |
P/E | negative | |
EV/Sales | 45.68 |
23 Analysts have issued a Kymera Therapeutics Inc forecast for earnings per share. The average Kymera Therapeutics Inc EPS is
This results in the following potential growth metrics and future valuations:
Kymera Therapeutics Inc...
Analyst | Rating | Action | Date |
---|---|---|---|
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Sep 18 2025 |
Barclays |
Locked
➜
Locked
|
Locked | Sep 17 2025 |
RBC Capital |
Locked
➜
Locked
|
Locked | Sep 16 2025 |
Oppenheimer |
Locked
➜
Locked
|
Locked | Jun 27 2025 |
Wells Fargo |
Locked
➜
Locked
|
Locked | Jun 26 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jun 26 2025 |
JP Morgan |
Locked
➜
Locked
|
Locked | Jun 03 2025 |
Analyst Rating | Date |
---|---|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Sep 18 2025 |
Locked
Barclays:
Locked
➜
Locked
|
Sep 17 2025 |
Locked
RBC Capital:
Locked
➜
Locked
|
Sep 16 2025 |
Locked
Oppenheimer:
Locked
➜
Locked
|
Jun 27 2025 |
Locked
Wells Fargo:
Locked
➜
Locked
|
Jun 26 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jun 26 2025 |
Locked
JP Morgan:
Locked
➜
Locked
|
Jun 03 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.